MYGN:NASDAQMyriad Genetics, Inc. Analysis

Myriad Genetics (MYGN) is trading well below its 20‑day (≈$4.67) and 50‑day (≈$4.75) moving averages, yet remains above the identified support at $4.20, indicating limited downside room in the near term. Technical momentum is mixed: the MACD histogram is positive and the signal line turned bullish, while the RSI sits around 57, suggesting the stock is not yet overbought. Volume has been trending down, and the beta of ~1.7 signals heightened price swings relative to the market. Fundamentally, the company reports negative profit margins, operating losses and negative cash flow, but forward EPS is projected positive, yielding a forward P/E of ~32 versus an industry average of ~26. Analysts see a ~49% upside target (mean $7.58) despite the current lack of dividend and a “hold” consensus. Recent material news highlights FDA approval of the MyChoice CDx companion diagnostic, a catalyst that could improve revenue growth and mitigate some of the bearish technical bias.
Overall, the stock sits at the intersection of a high‑risk, high‑potential profile: technical signs of short‑term weakness, a volatile earnings backdrop, but a meaningful regulatory win that could spark a longer‑term recovery if the company can translate approvals into sustainable sales.